Guzzle No More: GLP-1 Is Here to Save Happy Hour and Your Liver!

Hey Peptide Enthusiasts,

Welcome back to The Peptide Insider! Fasten your seatbelts (or at least your suspenders if you're old school), because we're about to dive into how GLP-1 receptor agonists are poised to shake things up with Alcohol Dependency!

So, what's the big deal? Picture this: you're at your local ASCP Annual Meeting—not exactly Coachella, I know—but this is where the magic happens for us peptide nerds. Mehdi Farokhnia, MD, MPH, of NIH, NIDA, and NIAAA, gave a jaw-dropping update on GLP-1 receptor agonists and their jaw-breaking potential for treating Alcohol Use Disorder (AUD).

Hold your horses; we aren't talking about something from the sci-fi realm. We're talking real science! In his presentation, Dr. Farokhnia shared some blockbuster data showing that GLP-1 receptor agonists significantly reduce alcohol intake in both rodent models and early human studies .Yep, those little critters are cutting back on happy hour, too.

And before you think, “Oh, that’s only rodents; what about us humans?” brace yourself for the kicker! Real-world data from the U.S. Department of Veterans Affairs echoes these findings—GLP-1 receptor agonists are indeed cutting down the booze consumption in actual people.

I know, I know—clinical trials are still ongoing, but we are on the cusp of adding another powerful weapon in our anti-AUD arsenal. Just imagine the possibilities: fewer regretful karaoke nights and more productive mornings. Until these trials wrap up, remember that we already have FDA-approved options for AUD, but hey, a new tool in the toolbox is always welcome.

So, kick back, enjoy these early wins, and stay tuned. Let’s all toast (with water, of course) to a future where peptides aren’t just life-changing—they’re culture-changing! Keep those confidence levels high, dear readers, because the GLP-1 revolution has just begun, and it's looking bigger than a Vegas buffet!

read the article here: https://www.psychiatrictimes.com/view/an-update-on-glp-1-receptor-agonists-as-pharmacotherapies-for-aud

Until next time, Sean Davis

Stay peppy, pals!

P.S. If you haven’t subscribed to The Peptide Insider yet, what are you waiting for? Get the latest scoop right in your inbox!